BioCentury
ARTICLE | Clinical News

INCB18424: Phase IIb data

September 28, 2009 7:00 AM UTC

Top-line data from a double-blind Phase IIb trial in 200 patients showed that all 3 doses of once-daily topical INCB18424 met the primary endpoint of significantly reducing total lesion score, as mea...